Introduction
============

Retinitis pigmentosa (RP) is a heterogeneous disease group of progressive hereditary retinal degeneration. It is clinically characterized by night blindness and peripheral concentric visual field defects and abnormal electroretinogram responses due to photoreceptor cell degeneration.[@b1-opth-4-569] Markedly decreased retinal blood flow has been reported.[@b2-opth-4-569]--[@b5-opth-4-569] This suggests that impaired retinal hemodynamics may be involved in the pathophysiology of RP. However, the pathologic and biochemical mechanisms involved have not yet been elucidated. A preliminary study has demonstrated that plasma endothelin-1 (ET-1), a very potent vasoconstrictor, is significantly elevated in RP patients when compared with control subjects.[@b6-opth-4-569] It was suggested that elevated ET-1 could lead to vasoconstriction and decrease in retinal blood flow, resulting in further deterioration of retinal degeneration. Thus, it is of much interest to test plasma ET-1 levels in various types of RP patients to elucidate the pathophysiologic significance of ET-1 in the etiology of RP. In the present study, we investigated serum ET-1 levels in 50 RP patients of differing genotypes and at various stages of the disease.

Patients and methods
====================

Patients
--------

Fifty RP patients (32 sporadic RP \[SRP\], nine autosomal dominant RP \[ADRP\], seven autosomal recessive RP \[ARRP\], one X-linked RP, one Biedl-Bardet syndrome) aged 56.4 ± 15 years, and 20 healthy-eye control subjects, aged 55.8 ± 8 years, with no history of systemic hypertension or diabetes mellitus were recruited. Informed consent was obtained from all subjects. The study was performed in accordance with our institution's guidelines and the Declaration of Helsinki on Biomedical Research Involving Human Subjects, and the protocol was approved by the Clinical Research Ethics Board of the Hirosaki University Hospital and Sapporo Medical University Hospital, and their Committees for the Protection of Human Subjects.

After the subjects had rested in the sitting position for 30 minutes, venous blood samples (5 mL) were taken and plasma was then separated out by centrifugation and frozen at −30°C. Prior to measuring the concentration of plasma ET-1, the frozen plasma samples were thawed, and subjected to the Parameter^®^ (R and D Systems, Minneapolis, MN) human ET-1 immunoassay kit. This assay used the quantitative enzyme immunoassay technique. An antibody specific for ET-1 was precoated onto a microplate. Standards, samples, controls, and conjugate were pipetted into wells and any ET-1 present was sandwiched by the immobilized antibody and the enzyme-linked antibody specific for ET-1. Following a wash to remove any unbound substances and/or antibody-enzyme reagents, substrate was added to the wells and color developed in proportion to the amount of ET-1 binding. The color development was stopped and the intensity of the color was measured by microplate reader. The measurements were performed in triplicate. Visual fields were examined by Humphrey SITA standard 10-2 threshold automated perimetry (Humphrey Instruments Inc., San Leandro, CA).

Statistical analysis
--------------------

All values are expressed as the mean ± standard deviation (SD) of at least three independent experiments. Data were statistically analyzed with the Mann-Whitney *U* test for comparison of all groups. Statistical significance was determined as *P* \< 0.01.

Results
=======

The clinical characteristics of 50 RP patients including genotypes, age, gender, visual acuity, and mean defect (MD) for the 10.2 visual field are summarized in [Table 1](#t1-opth-4-569){ref-type="table"}. Mean plasma ET-1 concentrations in RP patients (1.88 ± 0.30 pg/mL) were lower than those of healthy-eye control subjects (2.30 ± 0.30). As shown in [Table 1](#t1-opth-4-569){ref-type="table"}, significantly higher (\>2.6 pg/mL) and lower (\<2.0 pg/mL) ET-1 concentrations were recognized in eight and 31 RP patients, respectively. These levels were not statistically different among various genetic types of RP (ADRP, ARRP, and SRP).

In terms of the relationship between plasma ET-1 levels and clinical factors in RP, mean plasma ET-1 levels of more deteriorated in visual acuity ([Table 2](#t2-opth-4-569){ref-type="table"}), and visual field MD ([Table 3](#t3-opth-4-569){ref-type="table"}) was lower than those in the relatively preserved vision group. However, plasma ET-1 values in each patient were variable, and patients with significantly higher and lower ET-1 values did not always show better or worse visual characteristics as above.

Discussion
==========

ET-1 is produced by vascular endothelial cells and known to be a potent vasoconstrictive peptide.[@b7-opth-4-569] It has been shown that ET-1 receptors are present in human uveal tissues,[@b8-opth-4-569] the retina, and optic nerve heads,[@b9-opth-4-569] suggesting that ET-1 may have several physiologic and pathologic roles in the eye. It has been previously reported that abnormal plasma ET-1 levels are found in several ocular diseases, including glaucoma[@b10-opth-4-569],[@b11-opth-4-569] and retinal diseases such as diabetic retinopathy,[@b12-opth-4-569] retinal vein/artery occlusion, and proliferative vitreoretinopathy,[@b13-opth-4-569] in which ocular blood circulation is primarily involved in their pathology.

It was difficult to determine intraocular concentrations of ET-1, because intraocular fluid is necessary. In a previous study, it was reported that ET-1 was recognized in the subretinal fluid of patients with proliferative vitreoretinopathy, and its concentrations were significantly correlated with plasma ET-1 concentrations.[@b13-opth-4-569] If this is the case, because ET-1 within the peripheral blood circulation most likely penetrates into the intraocular cavity, intraocular ET-1 levels must correlate with plasma ET-1 levels. This suggests that ET-1 is indeed involved in the pathogenesis of several ocular diseases, including RP, and the plasma ET-1 level is a useful marker for evaluation of intraocular hemodynamics. Cellini et al have reported that plasma ET-1 levels were significantly higher in RP patients than those in control subjects,[@b6-opth-4-569] suggesting that an increase in plasma ET-1 may lead to vasoconstriction, resulting in a decrease in retinal blood flow.[@b3-opth-4-569] This suggests that abnormally higher levels of plasma ET-1 may also be involved in the pathology of retinal degenerative disease, in addition to the ocular vascular diseases mentioned above. However, in the present study, plasma ET-1 levels of RP patients were not higher than those in the healthy-eye control subjects, and the plasma ET-1 values varied in individual patients. Thus, the contribution of plasma ET-1 levels in the etiology of RP may not be as important as previously suggested.[@b6-opth-4-569] With regard to the differences between our data and those of others, several possibilities, including different assay systems, race, disease heterogeneity, and disease stages may be involved. In terms of the assay system used, the plasma ET-1 levels of RP patients in our study were comparable with those of Cellini et al but those of our control subjects were significantly lower than levels reported for previous studies.[@b6-opth-4-569],[@b11-opth-4-569],[@b14-opth-4-569]

Marked attenuation of retinal vessels with sclerotic and atrophic changes of the choriocapillaris layer have been documented in RP.[@b15-opth-4-569]--[@b17-opth-4-569] In addition, several morphologic studies have shown thickening of the extracellular matrix surrounding retinal vessels, especially in areas where translocated retinal pigment epithelial cells are close to the vessels following the progressive loss of photoreceptor cells.[@b18-opth-4-569] On the other hand, several hemodynamic studies have revealed that retinal blood flow is markedly decreased in RP patients compared with normal control subjects.[@b2-opth-4-569]--[@b5-opth-4-569] This change in retinal blood flow is quite reasonable because of significant sclerosis of the retinal and choroidal vessels, and the lower requirement for blood flow following degeneration of oxygen-consuming photoreceptors and thinning of the outer retina. Taking all these observations into consideration, it is thought that ET-1 may also be involved in the pathogenesis of RP, as postulated by Cellini et al.[@b6-opth-4-569] However, the data from our present series of patients suggests that its contribution may be more complex and variable in such a heterogeneous disease group. Thus, evaluating plasma ET-1 levels will contribute to additional insights into the retinal hemodynamics of RP and to development of new therapeutic strategies for preventing retinal degeneration in RP.
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###### 

Clinical characteristics and serum ET-1 levels in 50 RP patients

  **Age**   **Visual acuity (R/L)**   **Genetic type**   **Visual field MD (dB) (R/L)**   **ET-1 (pg/mL)**
  --------- ------------------------- ------------------ -------------------------------- ------------------
  71        HM/HM                     ADRP               n.d.                             2.14
  45        0.02/0.02                 ADRP               n.d.                             1.57
  49        0.06/0.06                 ADRP               n.d.                             2.3
  50        HM/0.3                    ADRP               n.d.                             0.71
  50        0.3/0.3                   ADRP               −35.36/−35.26                    2.63
  43        0.1/0.4                   ADRP               −12.14/−9.12                     1.9
  72        0.4/0.4                   ADRP               −16.32/−16.33                    1.99
  60        0.5/0.5                   ADRP               −16.21/−19.49                    1.66
  60        0.7/0.7                   ADRP               −24.34/−24.60                    1.87
  52        HM/HM                     ARRP               −35.06/−35.18                    2.55
  61        0.02/0.02                 ARRP               n.d.                             1.95
  72        0.05/0.05                 ARRP               n.d.                             2.18
  70        0.1/0.1                   ARRP               n.d.                             1.54
  49        0.15/0.15                 ARRP               −19.90/−19,58                    1.8
  61        0.2/0.2                   ARRP               −31.39/−37.72                    1.42
  50        1.0/0.9                   ARP                −0.49/−1.78                      2.36
  63        0.4/0.4                   XLRP carrier       n.d.                             0.83
  23        0.05/0.09                 Biedl-Bardet       n.d.                             1.81
  75        LP/LP                     SP                 n.d.                             2.09
  65        HM/HM                     SP                 n.d.                             2.13
  34        0.03/0.02                 SP                 −13.07/−16.00                    3.44
  74        0.09/0.05                 SP                 −15.30/−16.14                    1.74
  56        0.02/0.1                  SP                 −18.30/−19.61                    0.85
  80        0.1/0.1                   SP                 n.d.                             2.3
  71        0.1/0.1                   SP                 −23.46/−22.71                    1.88
  73        0.2/0.03                  SP                 n.d.                             1.11
  71        0.2/0.2                   SP                 −27.58/−23.97                    1.42
  57        0.02/0.2                  SP                 −11.11/−9.84                     2.61
  49        0.01/0.3                  SP                 −1.97/−3.41                      1.23
  72        0.1/0.3                   SP                 n.d.                             1.74
  49        0.2/0.3                   SP                 −27.37/−24.82                    0.98
  82        0.3/0.3                   SP                 n.d.                             1.93
  49        0.4/0.3                   SP                 −20.62/−22.50                    2.76
  59        0.5/0.3                   SP                 −32.02/−33.10                    1.45
  56        0.4/0.5                   SP                 −31.36/−33.64                    1.66
  28        0.5/0.4                   SP                 n.d.                             1.96
  62        0.4/0.5                   SP                 −13.40/−17.64                    1.56
  76        0.5/0.6                   SP                 −31.66/−31.22                    1.67
  39        0.7/0.7                   SP                 −10.22/−25.48                    1.87
  65        0.7/0.7                   SP                 −10.22/−8.66                     2.67
  74        0.7/0.7                   SP                 −20.91/−3.33                     2.42
  32        0.8/0.7                   SP                 n.d.                             2.05
  58        0.8/0.7                   SP                 −8.17/−5.00                      2.85
  55        0.9/0.9                   SP                 −0.77/−2.10                      2.55
  34        0.9/0.9                   SP                 −4.44/−6.29                      1.84
  28        0.9/0.9                   SP                 −14.39/−16.53                    2.09
  54        1.2/1.2                   SP                 −8.83/−11.07                     1.53
  49        1.2/1.2                   SP                 −13.35/−11.51                    1.47
  27        1.2/1.2                   SP                 −18.74/−14.46                    2.06
  66        n.d.                      n.d.               n.d.                             1.05

**Abbreviations:** ET-1, endothelin-1; HM, hand motion; LP, light perception; RP, retinitis pigmentosa; ADRP, autosomal dominant RP; ARRP, autosomal recessive RP; SP, sporadic RP; XLRP, X-linked RP; n.d., not determined.

###### 

Serum ET-1 levels and visual acuity in RP patients

                       **Visual acuity**                 
  -------------------- ------------------- ------------- -------------
  Serum ET-1 (pg/mL)   1.81 ± 0.62         1.83 ± 0.51   2.12 ± 0.40

**Notes:** Better visual acuity among both eyes was enrolled. A statistically significant difference (*P* \> 0.01) was observed between \<0.2 and \>0.7.

**Abbreviations:** ET-1, endothelin-1; RP, retinitis pigmentosa.

###### 

Serum ET-1 levels and visual field

                       **Visual field MD**   **(10-2)**
  -------------------- --------------------- -------------
  Serum ET-1 (pg/mL)   1.77 ± 0.53           2.14 ± 0.59

**Notes:** Worse MD among both eyes was enrolled. A statistically significant difference (*P* \> 0.01) was observed between the two groups.

**Abbreviations:** ET-1, endothelin-1; MD, mean defect.
